Targeting latency-associated peptide promotes antitumor immunity

See allHide authors and affiliations

Science Immunology  19 May 2017:
Vol. 2, Issue 11, eaaj1738
DOI: 10.1126/sciimmunol.aaj1738

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

LAPping up tumor immunoregulation

Tumors dodge the immune system in part by promoting immune regulatory cells. Gabriely et al. now report that antibodies to latency-associated peptide (LAP), which forms a complex with transforming growth factor–β (TGF-β), reduced tumor growth in multiple cancer models in mice. The authors found that antibodies to LAP decreased numbers of LAP+ regulatory T cells and tolerogenic dendritic cells within the tumor and TGF-β secretion in vitro. Moreover, anti-LAP antibodies decreased numbers of CD103+ CD8+ T cells in lymphoid organs; these cells were then shown to promote tumor growth. Furthermore, combining LAP antibodies with antigen-specific vaccination enhanced both antitumor immune response and immunological memory. Together, these data suggest that targeting LAP may enhance tumor immunotherapy.